| Project/Area Number |
24590719
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Laboratory medicine
|
|---|
| Research Institution | Department of Clinical Research, National Hospital Organization Kyoto Medical Center |
|---|
Principal Investigator |
NORIKO Satoh 独立行政法人国立病院機構(京都医療センター臨床研究センター), 糖尿病研究部, 研究室長(臨床代謝栄養) (80373512)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HASEGAWA Koji 独立行政法人国立病院機構, 京都医療センター臨床研究センター展開医療研究部, 部長 (50283594)
KOTANI Kazuhiko 自治医科大学, 臨床検査医学, 准教授 (60335510)
|
|---|
| Research Collaborator |
TSUKAHARA Tetsuya 独立行政法人国立病院機構, 京都医療センター脳神経外科, 副院長
YAMAGUCHI Takashi 独立行政法人国立病院機構, 京都医療センター外科, 医長
HATA Hiroaki 独立行政法人国立病院機構, 京都医療センター外科, 医員
ARATA Jyun 独立行政法人国立病院機構, 京都医療センター形成外科, 医長
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | マクロファージ / 肥満 / 2型糖尿病 / 血管合併症 / 炎症 / 臨床研究 / 単球 / 糖尿病 / 肥満症 |
|---|
| Outline of Final Research Achievements |
In this study, in obese and diabetic patients among two multicenter prospective cohorts of JOMS and J-DOS with 1334 obesity and/or diabetes patients which we established, the function of peripheral blood monocyte (inflammatory M1/ anti-inflammatory M2 type balance) were deteriorated. This was found to be in accordance with an increase in novel oxidized LDL and CAVI (Diabetes Care, 2010). In addition, we revealed that a DPP4 inhibitor and the medication for dyslipidemia, EPA, improved the M1/ M2 ratio in the monocyte, thereby leading to their anti-atherogenic effects (Diabetes Care, 2012, 2013, Metabolism, 2013). Furthermore, monocyte M1/M2 type ratios were associated with the inflammation degree of the carotid plaque in patients undergoing carotid endarterectomy. Therefore, we can suggest the a treatment program including a novel cardiovascular risk marker system focusing on monocyte function (M1/M2 type).
|
